The US medical devices industry saw a drop of 4.2% in overall deal activity during April 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 68 deals worth $797.35m were announced in April 2019, compared to the 12-month average of 71 deals.
Venture financing was the leading category in the month in terms of volume with 52 deals which accounted for 76.5% of all deals.
In second place was M&A with ten deals, followed by private equity with six transactions, respectively accounting for 14.7% and 8.8% of overall deal activity in the country’s medical devices industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, venture financing was the leading deal category in the US medical devices industry with total deals worth $473.86m, while M&A and private equity deals totalled $170.3m and $153.19m, respectively.
US medical devices industry deals in April 2019: Top deals
The top five medical devices industry deals accounted for 56% of the overall value during April 2019.
The combined value of the top five medical devices industry deals stood at $446.5m, against the overall value of $797.35m recorded for the month. The top announced US medical devices industry deal tracked by GlobalData in April 2019 was Medline Industries’ $167.5m asset transaction with AngioDynamics.
In second place was the $100m private equity deal with NorthStar Medical Radioisotopes by Oberland Capital Management and in third place was Ally Bridge Group, ArrowMark Partners, Driehaus Capital Management and RTW Investments’ $65m venture financing of Pulmonx.
The $60m venture financing of PathAI by General Atlantic and General Catalyst Partners and Fred Moll, Johnson & Johnson Innovation – JJDC, Lumira Capital Investment Management, State of Wisconsin Investment Board, Varian Medical Systems and Venture Investors’ venture financing of HistoSonics for $54m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
